DreaMed Diabetes said today that U.S. FDA has granted a de novo request for DreaMed Advisor Pro, its AI-based diabetes treatment decision support software.
The news comes about four months after the Petah Tikva, Israel–based company won CE Mark clearance for the decision-support platform, which is meant to help healthcare professionals manage insulin therapy for people with Type I diabetes.
Get the full story on our sister site Drug Delivery Business News.
The post DreaMed Diabetes wins FDA authorization to market insulin therapy management platform appeared first on MassDevice.
from MassDevice https://ift.tt/2JX6j3h
Cap comentari:
Publica un comentari a l'entrada